AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Dec 2021 07:00 AM
RNS
AstraZeneca, Ionis to collaborate on eplontersen
01 Dec 2021 03:00 PM
RNS
Total Voting Rights
01 Dec 2021 03:00 PM
RNS
Block listing Interim Review
30 Nov 2021 07:00 AM
RNS
Lynparza granted FDA Priority Review for OlympiA
15 Nov 2021 04:00 PM
RNS
Director/PDMR Shareholding
12 Nov 2021 07:00 AM
RNS
AZN: Year to date and Q3 2021 results
01 Nov 2021 03:00 PM
RNS
Total Voting Rights
01 Nov 2021 07:00 AM
RNS
AstraZeneca to transfer rights to Eklira, Duaklir
25 Oct 2021 07:00 AM
RNS
Imfinzi improved survival in biliary tract cancer
18 Oct 2021 07:00 AM
RNS
AZ recommends ADS holders reject mini-tender offer
15 Oct 2021 07:00 AM
RNS
Imfinzi & tremelimumab improved OS in liver cancer
11 Oct 2021 07:00 AM
RNS
AZD7442 PhIII trial positive in COVID outpatients
04 Oct 2021 07:00 AM
RNS
Enhertu granted BTD for breast cancer
01 Oct 2021 03:00 PM
RNS
Total Voting Rights
30 Sep 2021 04:00 PM
RNS
Director/PDMR Shareholding
29 Sep 2021 07:00 AM
RNS
AstraZeneca to fully acquire Caelum Biosciences
28 Sep 2021 07:00 AM
RNS
Saphnelo approved in Japan for SLE
24 Sep 2021 07:00 AM
RNS
Lynparza PROpel trial meets primary endpoint
23 Sep 2021 07:00 AM
RNS
Board Committee Change
23 Sep 2021 07:00 AM
RNS
New Sustainability Committee of the Board
21 Sep 2021 07:00 AM
RNS
AstraZeneca $360m Irish manufacturing investment
20 Sep 2021 07:00 AM
RNS
Enhertu reduced risk of disease progression by 72%
09 Sep 2021 04:00 PM
RNS
Imfinzi improves survival in NSCLC in POSEIDON
09 Sep 2021 07:00 AM
RNS
PT027 PhIII asthma trials met primary endpoints
03 Sep 2021 07:00 AM
RNS
Ultomiris approved in EU for children with PNH
01 Sep 2021 03:00 PM
RNS
Total Voting Rights
26 Aug 2021 07:05 AM
RNS
Forxiga approved in Japan for CKD
26 Aug 2021 07:00 AM
RNS
ALXN1840 Wilson Phase III met primary endpoint
20 Aug 2021 07:05 AM
RNS
Update on Ultomiris Phase III ALS trial
20 Aug 2021 07:00 AM
RNS
AZD7442 prophylaxis trial met primary endpoint
16 Aug 2021 03:00 PM
RNS
Director/PDMR Shareholding
11 Aug 2021 02:35 PM
RNS
Update on US review of roxadustat
09 Aug 2021 07:05 AM
RNS
Forxiga approved in the EU for CKD
09 Aug 2021 07:00 AM
RNS
Enhertu head-to-head trial meets primary endpoint
02 Aug 2021 03:00 PM
RNS
Total Voting Rights
02 Aug 2021 07:00 AM
RNS
Saphnelo approved in the US for SLE
29 Jul 2021 07:00 AM
RNS
AZN: H1 2021 Results
26 Jul 2021 07:00 AM
RNS
Ultomiris recommended in EU for children with PNH
22 Jul 2021 07:00 AM
RNS
Directorate Change
21 Jul 2021 03:56 PM
RNS
Director/PDMR Shareholding
21 Jul 2021 03:45 PM
RNS
Total Voting Rights
21 Jul 2021 01:45 PM
RNS
Acquisition of Alexion completed
19 Jul 2021 07:00 AM
RNS
Imfinzi approved in China for extensive-stage SCLC
16 Jul 2021 07:00 AM
RNS
Status on US FDA Advisory Committee for roxadustat
14 Jul 2021 07:08 AM
RNS
AstraZeneca-Alexion transaction cleared in the UK
08 Jul 2021 07:00 AM
RNS
Tezepelumab granted FDA Priority Review for asthma
06 Jul 2021 07:00 AM
RNS
AstraZeneca-Alexion transaction cleared in the EU
01 Jul 2021 03:00 PM
RNS
Total Voting Rights
28 Jun 2021 07:05 AM
RNS
Forxiga recommended in EU for patients with CKD
28 Jun 2021 07:00 AM
RNS
Nirsevimab PhII/III trial confirms safety profile
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100